ERA-EDTA Symposium 2018

Read story

ESC Congress 2017

Read story

ERA-EDTA Congress 2017

Read story

ESC Congress 2016

Read story

EASD 2016

Read story

European Biopharmaceutical Review

Read story

New York Academy of Science Symposium

Read story

The Complement System: Part 1

Read story

The Complement System: Part 2

Read story

The Complement System: Part 3

Read story

Diabetes Mellitus

Read story

Chronic Kidney Disease

Read story

The New Frontier of Epigenetics

Read story

Readers, Writers & Erasers in Epigenetics

Read story

Clinical Trials Series: Part 1

Read story

Clinical Trials Series: Part 2

Read story

Clinical Trials Series: Part 3

Read story

Pharmacoeconomics

Read story

Sanofi Biogenius Competition CTV News feature

Read story

World Diabetes Day

Read story

ERA-EDTA Symposium 2018

On May 25, 2018, Resverlogix supported a symposium at the European Renal Association – European Dialysis and Transplant Association (ERA‐EDTA) Congress in Copenhagen, Denmark: "Epigenetics in CKD & CVD: A potential breakthrough therapy?”

Symposium Agenda

Introduction - Vincent M. Brandenburg, MD – University Hospital of the RWTH Aachen, Germany.

Kamyar Kalantar-Zadeh, MD – UC Irvine School of Medicine, Irvine, CA, USA. "A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives."

Erik Stroes, MD – Academic Medical Centre, Amsterdam, The Netherlands. "Cardiovascular disease in diabetes and CKD & residual risk - The promise of epigenetics." 

Louise Nordfors, PhD – Karolinska Institute, Stockholm, Sweden. "Epigenetics in CKD: Rationale for BET inhibition, an emerging therapeutic mechanism in renal disease and CVD."

Video Presentations and Symposium Highlights can be accessed HERE